Specifically, the αAMTN-dFGF2V1V2-MMAE conjugate effectively kills cancer cells with high levels of FGFR1 while exhibiting minimal toxicity towards FGFR1-deficient cells. This evidence concerns the gene FGFR1 and cancer.